On 6/26/24, Fate Therapeutics Inc (NASDAQ: FATE) stock suffered a major decline of -12.4%, closing at $3.26. However, this decline was accompanied by unusually low trading volume at 65% of normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -8.7% during the last week.
Current PriceTarget Research Rating
FATE’s future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to be Value Creation neutral.
Fate Therapeutics has a current Value Trend Rating of B (Positive). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Fate Therapeutics has a poor Appreciation Score of 30 but a very high Power Rating of 99, producing the Positive Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment